References

References: Interstitial I · The Thalidomide Children

  1. Stephens TD & Brynner R, 'Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine,' Perseus, 2001.
  2. Thalidomide scandal — Wikipedia.
  3. Grünenthal GmbH — corporate history.
  4. Stephens TD & Brynner R, 'Dark Remedy,' Perseus, 2001 — Ch. 1 on Grünenthal's internal sign-off for thalidomide.
  5. Kim JH & Scialli AR, 'Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease,' Toxicological Sciences 122(1): 1–6, 2011.
  6. Grünenthal GmbH — official corporate history.
  7. Thalidomide — Wikipedia.
  8. Grünenthal GmbH — corporate history (penicillin production from the late 1940s).
  9. Daemmrich A, 'A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany,' Social History of Medicine 15(1): 137–158, 2002.
  10. PubChem CID 5426 — Thalidomide, NCBI.
  11. Thalidomide — Wikipedia (naming and chemistry).
  12. Stephens TD & Brynner R, 'Dark Remedy,' Perseus, 2001 — Ch. 1 on Grünenthal's internal sign-off.
  13. Kim JH & Scialli AR, Toxicological Sciences 122(1): 1–6, 2011.
  14. Stephens TD & Brynner R, 'Dark Remedy,' Perseus, 2001.
  15. Vargesson N, 'Thalidomide-induced teratogenesis: history and mechanisms,' Birth Defects Research C 105(2): 140–156, 2015.
  16. Thalidomide scandal — Wikipedia ('sold over the counter in West Germany').
  17. Daemmrich A, Social History of Medicine 15(1): 137–158, 2002.
  18. Vargesson N, 'Thalidomide-Induced Teratogenesis: History and Mechanisms,' Birth Defects Res C Embryo Today 105(2):140-156, 2015.
  19. Stephens T, Brynner R, 'Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine,' Perseus, 2001.
  20. Sjöström H, Nilsson R, 'Thalidomide and the Power of the Drug Companies,' Penguin, 1972.
  21. Grünenthal GmbH, official corporate "History" page: "In 1957, the sleep and sedative drug Thalidomide (marketed as Contergan in Germany) is introduced to the market."
  22. Thalidomide Trust (UK), 'About Thalidomide.'
  23. Vargesson N, Birth Defects Research C 105(2): 140–156, 2015.
  24. López-Muñoz F, Ucha-Udabe R, Alamo C, 'The history of barbiturates a century after their clinical introduction,' Neuropsychiatric Disease and Treatment 1(4): 329–343, 2005.
  25. Kim JH, Scialli AR, 'Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease,' Toxicol Sci 122(1):1-6, 2011.
  26. Lenz W, 'A short history of thalidomide embryopathy,' Teratology 38(3): 203–215, 1988.
  27. McBride WG, 'Thalidomide and congenital abnormalities,' The Lancet 278(7216): 1358, 1961.
  28. Bermejo-Sánchez E et al., 'Phocomelia: a worldwide descriptive epidemiologic study... International Clearinghouse for Birth Defects Surveillance and Research,' Am J Med Genet C 157C(4): 305–320, 2011.
  29. Pakkasjärvi N et al., 'Amelia and phocomelia in Finland: characteristics and prevalences in a nationwide population-based study,' 2023.
  30. Newman CGH, 'The thalidomide syndrome: risks of exposure and spectrum of malformations,' Clinics in Perinatology 13(3): 555–573, 1986.
  31. Newman CGH, Clinics in Perinatology 13(3): 555–573, 1986.
  32. Whittick GC, 'The Earliest Roman Lead-Mining on Mendip and in North Wales,' Britannia 13: 113-123, 1982.
  33. Mattingly DJ, An Imperial Possession: Britain in the Roman Empire, Penguin, 2006.
  34. Vargesson N., 'Thalidomide: history, withdrawal, renaissance, and safety concerns,' Expert Opinion on Drug Safety (2021).
  35. Ito T, Ando H, Suzuki T, et al., 'Identification of a primary target of thalidomide teratogenicity,' Science 327(5971): 1345–1350, 2010.
  36. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N, PNAS 106(21): 8573–8578, 2009.
  37. Eriksson T, Björkman S, Höglund P, 'Clinical pharmacology of thalidomide,' European Journal of Clinical Pharmacology 57(5): 365–376, 2001.
  38. Therapontos C et al., PNAS 106(21): 8573–8578, 2009.
  39. Lenz W, Teratology 38(3): 203–215, 1988.
  40. Gilbert SF & Barresi MJF, 'Developmental Biology,' 12th ed., Sinauer/Oxford, 2020.
  41. Wolpert L, Tickle C, Martinez Arias A, 'Principles of Development,' 6th ed., Oxford, 2019.
  42. Newman CGH, 'The Thalidomide Syndrome: Risks of Exposure and Spectrum of Malformations,' Clin Perinatol 13(3):555-573, 1986.
  43. U.S. FDA, 'Frances Oldham Kelsey: Medical Reviewer Famous for Averting a Public Health Tragedy.'
  44. AMA Journal of Ethics, 'Protecting the Public: Dr. Frances Oldham Kelsey,' 2001.
  45. Frances Oldham Kelsey, Wikipedia
  46. Geeta Anand et al., 'Was Thalidomide Safe? Frances Oldham Kelsey Was Not Convinced,' Scientific American
  47. 'Frances Kathleen Oldham Kelsey,' National Women's History Museum
  48. AMA Journal of Ethics, 2001.
  49. U.S. FDA, 'Frances Oldham Kelsey: Medical Reviewer...'
  50. 'Frances Oldham Kelsey's refusal to approve thalidomide changed medical history,' The 19th, Oct. 2025.
  51. U.S. FDA. 'Guidance for Industry: Action Level for Inorganic Arsenic in Apple Juice.' June 2023.
  52. U.S. FDA. 'Arsenic in Food and Dietary Supplements.'
  53. Kelsey FO, 'Thalidomide update: regulatory aspects,' Teratology 38(3): 221–226, 1988.
  54. Mintz M, 'Heroine of FDA Keeps Bad Drug Off Market,' The Washington Post, July 15, 1962.
  55. Kelsey FO, Teratology 38(3): 221–226, 1988.
  56. Lenz W, 'Kindliche Missbildungen nach Medikament-Einnahme während der Gravidität?', Dtsch Med Wochenschr 86: 2555–2556, 1961.
  57. Thalidomide scandal — Wikipedia (Contergan withdrawn 27 Nov 1961).
  58. Vargesson N, 'Thalidomide Embryopathy: An Enigmatic Challenge,' ISRN Developmental Biology, vol. 2013, art. 241016.
  59. Wilson JG, 'Environment and Birth Defects,' Academic Press, 1973 — Wilson's principles of teratology.
  60. Brent RL, 'Environmental causes of human congenital malformations...,' Pediatrics 113(4 Suppl): 957–968, 2004.
  61. Brent RL, Pediatrics 113(4 Suppl): 957–968, 2004.
  62. Carlson BM, 'Human Embryology and Developmental Biology,' 6th ed., Elsevier, 2018.
  63. Moore KL, Persaud TVN, Torchia MG, 'The Developing Human: Clinically Oriented Embryology,' 11th ed., Elsevier, 2019.
  64. Phoenix CH, Goy RW, Gerall AA, Young WC. Organizing action of prenatally administered testosterone propionate on the tissues mediating mating behavior in the female guinea pig. Endocrinology. 1959;65(3):369-82.
  65. Arnold AP. The organizational-activational hypothesis as the foundation for a unified theory of sexual differentiation of all mammalian tissues. Horm Behav. 2009;55(5):570-78.
  66. Wallen K. The organizational hypothesis: reflections on the 50th anniversary of the publication of Phoenix, Goy, Gerall, and Young (1959). Horm Behav. 2009;55(5):561-65.
  67. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT. 'EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.' Endocrine Reviews 36(6): E1-E150, 2015.
  68. Vandenberg LN, Colborn T, Hayes TB, et al. 'Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses.' Endocrine Reviews 33(3): 378-455, 2012.
  69. Grandjean P, Landrigan PJ. 'Neurobehavioural effects of developmental toxicity.' The Lancet Neurology 13(3): 330-338, 2014.